<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We established two long-term human B-lymphoblastoid cell lines (L55 and L72) transformed by Epstein-Barr virus that produced IgM kappa antibodies to the human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> antigen, OFA-I </plain></SENT>
<SENT sid="1" pm="."><plain>Periphral blood lymphocytes obtained from <z:hpo ids='HP_0002861'>melanoma</z:hpo> patients were used as the source of the B lymphocytes </plain></SENT>
<SENT sid="2" pm="."><plain>Antibody specificity was determined by the immune adherence assay using various human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and noncancer tissues as targets </plain></SENT>
<SENT sid="3" pm="."><plain>L55 antibody (designated anti-OFA-I-1) reacted with a variety of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types whereas L72 antibody (designated anti-OFA-I-2) reacted only with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells of neuroectodermal origin (<z:hpo ids='HP_0002861'>melanoma</z:hpo>, <z:hpo ids='HP_0009733'>glioma</z:hpo>, and <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo>) </plain></SENT>
<SENT sid="4" pm="."><plain>The levels of IgM detected in the spent medium of 1 X 10(6) L55 and L72 cells were 4 and 9 micrograms/ml, respectively, by radioimmunoassay </plain></SENT>
</text></document>